 |
156 Diseases |  |
15 Trials |
|
15 Trials |  |
235 News |  |
| «1234» |
- ||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, cyclophosphamide oral / Generic mfg.
Clinical, P3 data, Journal, CINV: Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. (Pubmed Central) - Jun 12, 2020
P3
Oral NEPA was highly effective in preventing both acute and delayed CINV over multiple chemotherapy cycles of HEC, AC, and MEC regimens.
- ||| Clinical, P3 data, Journal, CINV: Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial. (Pubmed Central) - Apr 21, 2020
Both regimens were well tolerated and commonly reported adverse events (≥1%) were similar between these two group. Single-dose intravenous fosaprepitant (150 mg) combined with palonosetron and dexamethasone was well tolerated and demonstrated noninferior control of CINV to aprepitant-based triple regimen in Chinese patients treating with cisplatin-base chemotherapy.
- || Clinical, Observational data, Journal: Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. (Pubmed Central) - Mar 4, 2020
This is the second study that compared a 0.25 mg dose of palonosetron with first-generation setron in triplet antiemetic prophylaxis in cancer patients receiving HEC. We could not find meaningful statistical differences between two arms, regarding CR rate on acute and delayed CINV.
- || aprepitant oral / Generic mfg.
Clinical, Journal: Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. (Pubmed Central) - Jan 21, 2020
With a relative bioavailability of 82.3%, the extemporaneous aprepitant oral suspension was well-absorbed relative to the capsule. Though not bioequivalent to the oral capsule, the clinical use of this aprepitant oral suspension in adult and pediatric patients unable to swallow capsules is likely to be effective and safe.
- || aprepitant oral / Generic mfg.
Clinical, Journal: Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial. (Pubmed Central) - Jan 21, 2020
Though not bioequivalent to the oral capsule, the clinical use of this aprepitant oral suspension in adult and pediatric patients unable to swallow capsules is likely to be effective and safe. Aprepitant led to a significant improvement in cough in advanced lung cancer, without increasing severe side-effects.
- | dexamethasone / Generic mfg.
Trial completion, Surgery: Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting (clinicaltrials.gov) - Jan 2, 2020
P4, N=90, Completed, Sponsor: Ain Shams University
Aprepitant led to a significant improvement in cough in advanced lung cancer, without increasing severe side-effects. Not yet recruiting --> Completed
- || Clinical, Journal: The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. (Pubmed Central) - Dec 29, 2019
Rolapitant has a longer half-life (180 hours) than other commercially available NK-1 receptor antagonists and does not induce or inhibit CYP34A, unlike the other NK-1 receptor antagonists. Future studies may determine if these may be an important clinical issues.
- | aprepitant oral / generics
Clinical, Journal: A New Single-Item Sleep Quality Scale: Results of Psychometric Evaluation in Patients With Chronic Primary Insomnia and Depression. (Pubmed Central) - Dec 6, 2019
P3
Future studies may determine if these may be an important clinical issues. The SQS possesses favorable measurement characteristics relative to lengthier or more frequently administered sleep questionnaires in patients with insomnia and depression.
- || ondansetron / generics
Clinical, PK/PD data, Journal: Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects. (Pubmed Central) - Nov 19, 2019
P2b
PK, safety, and preliminary efficacy analyses support further clinical evaluation of aprepitant for PONV prophylaxis in pediatric patients. CLINICALTRIALS.
- | palonosetron intravenous / generics
Clinical, Journal, Combination therapy: Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. (Pubmed Central) - Sep 22, 2019
There was no difference between the groups in severity of nausea during the first 24 h after surgery (P > 0.05). : Aprepitant combined with palonosetron did not reduce the incidence of PONV as compared to palonosetron alone within 24 h of surgery in women receiving fentanyl-based IV-PCA.
- | olanzapine / Generic mfg.
New P3 trial: FORESIGHT: Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy (clinicaltrials.gov) - Sep 3, 2019
P3, N=60, Recruiting, Sponsor: CR-CSSS Champlain-Charles-Le Moyne
- | aprepitant oral / generics
Clinical, P2 data, Journal: Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). (Pubmed Central) - Aug 1, 2019
P2
...Patients were randomized to receive either first oral aprepitant 80 mg/day or placebo for 4 weeks...Under the experimental conditions of the study, aprepitant, 80 mg daily for 4 weeks, did not have an antipruritic effect in patients with chronic prurigo. (DRKS00005594; EudraCT Number: 2013-001601-85).
- | dexamethasone / Generic mfg.
New P4 trial, Surgery: Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting (clinicaltrials.gov) - Jul 8, 2019
P4, N=90, Not yet recruiting, Sponsor: Ain Shams University
- | dexamethasone / generics, ondansetron / generics
Clinical, Journal: Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial. (Pubmed Central) - Jul 4, 2019
Eighty milligrams of aprepitant added to a three-drug multimodal prophylaxis strategy can bring benefits to a high-risk population by reducing PONV episodes and rescue antiemetic requirements. This study was registered in the ClinicalTrials.gov (NCT 02357693) database.
- | olanzapine / Generic mfg.
Trial completion date, Trial primary completion date: Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients (clinicaltrials.gov) - May 22, 2019
P3, N=120, Active, not recruiting, Sponsor: CCTU
This study was registered in the ClinicalTrials.gov (NCT 02357693) database. Trial completion date: Feb 2020 --> Dec 2020 | Trial primary completion date: Feb 2019 --> Dec 2020
- | ondansetron / generics
Clinical, Journal, CINV: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. (Pubmed Central) - May 13, 2019
P3
Trial completion date: Feb 2020 --> Dec 2020 | Trial primary completion date: Feb 2019 --> Dec 2020 A 3 day aprepitant regimen seemed effective and safe for prevention of chemotherapy-induced nausea and vomiting in paediatric subjects across subgroups (ClinicalTrials.gov NCT01362530).
- | Trisenox (arsenic trioxide) / Teva, Medsenic
Journal: Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant. (Pubmed Central) - May 5, 2019
The stimulatory effect of NK1R inhibition on ATO cytotoxicity is probably mediated through up-regulation of p73, which can subsequently engage p21 and NF-κB pathway via transcriptional suppression of c-Myc. Taken together, the present study suggests that inhibition of NK1R using Aprepitant, either alone or in combination with chemotherapeutic drugs, could be a novel therapeutic strategy for the treatment of acute leukemia, especially APL, that may be clinically accessible in the near future.
- | hydroxyzine hydrochloride / Generic mfg.
Enrollment open: APHYPAP: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (clinicaltrials.gov) - Apr 21, 2019
P3, N=80, Recruiting, Sponsor: University Hospital, Brest
Taken together, the present study suggests that inhibition of NK1R using Aprepitant, either alone or in combination with chemotherapeutic drugs, could be a novel therapeutic strategy for the treatment of acute leukemia, especially APL, that may be clinically accessible in the near future. Not yet recruiting --> Recruiting
- | ondansetron / generics
Clinical, Journal: Comparing the efficacy of aprepitant and ondansetron for the prevention of postoperative nausea and vomiting (PONV): A double blinded, randomised control trial in patients undergoing breast and thyroid surgeries. (Pubmed Central) - Apr 20, 2019
A single dose of oral aprepitant has comparable effects to injection ondansetron administered eighth hourly in preventing PONV, the severity of nausea, number of rescue antiemetics, and the time to first emetic episode in the 24-h postoperative period. REF/2017/06/014637.
- | Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
Clinical, Journal: Evaluation of aprepitant and fosaprepitant in pediatric patients. (Pubmed Central) - Apr 13, 2019
Aprepitant and fosaprepitant were safely used and may be equally useful for pediatric patients receiving highly emetogenic chemotherapy. CR rate may be associated with patient age.
- || pramipexole ER (CTC-413) / Chase Therap
Enrollment open, Trial initiation date: A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) - Apr 11, 2019
P2, N=24, Recruiting, Sponsor: Chase Therapeutics Corporation
CR rate may be associated with patient age. Not yet recruiting --> Recruiting | Initiation date: Nov 2018 --> Apr 2019
- | olanzapine / Generic mfg.
New P3 trial: Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy (clinicaltrials.gov) - Mar 15, 2019
P3, N=147, Recruiting, Sponsor: Mahidol University
- | dexamethasone / Generic mfg., mirtazapine / Generic mfg.
Trial primary completion date: Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis (clinicaltrials.gov) - Feb 16, 2019
P3, N=212, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting | Initiation date: Nov 2018 --> Apr 2019 Trial primary completion date: Dec 2018 --> Dec 2019
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
New P4 trial, HEOR: Comparative Effectiveness of AKYNZEO (clinicaltrials.gov) - Feb 6, 2019
P4, N=426, Recruiting, Sponsor: VIFORFRANCE
- | melphalan / Generic mfg., olanzapine / Generic mfg.
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan (clinicaltrials.gov) - Jan 28, 2019
P3, N=429, Recruiting, Sponsor: Rush University Medical Center
Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting | Trial completion date: Nov 2018 --> Nov 2020 | Initiation date: Nov 2016 --> Sep 2017 | Trial primary completion date: Nov 2018 --> Nov 2020
- | hydroxyzine hydrochloride / Generic mfg.
New P3 trial: APHYPAP: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (clinicaltrials.gov) - Jan 18, 2019
P3, N=80, Not yet recruiting, Sponsor: University Hospital, Brest
- | Bridion (sugammadex) / Merck (MSD)
Trial completion date, Trial primary completion date: Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy (clinicaltrials.gov) - Jan 15, 2019
P4, N=82, Recruiting, Sponsor: Stony Brook University
Not yet recruiting --> Recruiting | Trial completion date: Nov 2018 --> Nov 2020 | Initiation date: Nov 2016 --> Sep 2017 | Trial primary completion date: Nov 2018 --> Nov 2020 Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Review, Journal, CINV: Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. (Pubmed Central) - Oct 18, 2018
To examine pharmacologic and clinical characteristics of neurokinin 1 (NK)-receptor antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy, a literature search was performed for clinical studies in patients at risk of CINV with any approved NK RAs in the title or abstract: aprepitant (capsules or oral suspension), HTX019 (intravenous [IV] aprepitant), fosaprepitant (IV aprepitant prodrug), rolapitant (tablets or IV), and fixed-dose tablets combining netupitant or fosnetupi-tant (IV netupitant prodrug) with the 5-hydroxytryptamine type 3 (5HT) RA palonosetron (oral or IV)...Adding an NK RA to 5HT RA and dexamethasone significantly improves CINV control vs the two-drug regimen. Newer NK RAs offer more formulation options, higher acute-phase plasma levels, or improved tolerability, and increase clinicians' opportunities to maximize benefits of this important class of antiemetics.
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion date, Trial primary completion date: Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=150, Recruiting, Sponsor: Vanderbilt University
Newer NK RAs offer more formulation options, higher acute-phase plasma levels, or improved tolerability, and increase clinicians' opportunities to maximize benefits of this important class of antiemetics. Trial completion date: Jul 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Mar 2020
- | olanzapine / Generic mfg.
Enrollment closed: Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients (clinicaltrials.gov) - Sep 25, 2018
P3, N=120, Active, not recruiting, Sponsor: CCTU
Trial completion date: Jul 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Mar 2020 Recruiting --> Active, not recruiting
- | pramipexole ER (CTC-413) / Chase Therap
New P2 trial: A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) - Sep 25, 2018
P2, N=24, Not yet recruiting, Sponsor: Chase Therapeutics Corporation
- | aprepitant oral / Generic mfg.
Trial completion: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers (clinicaltrials.gov) - Aug 29, 2018
P1, N=17, Completed, Sponsor: The Hospital for Sick Children
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- | 5-fluorouracil / Generic mfg., gemcitabine / Generic mfg.
Phase classification: Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer (clinicaltrials.gov) - Aug 15, 2018
P2, N=22, Completed, Sponsor: Wake Forest University Health Sciences
Not yet recruiting --> Completed Phase classification: P=N/A --> P2
- | Sancuso (granisetron) / Cumberland
Trial termination: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=4, Terminated, Sponsor: Gynecologic Oncology Group
Phase classification: P=N/A --> P2 Suspended --> Terminated; Study terminated due to no patient population available
- | olanzapine / Generic mfg.
New P2 trial: OlaCINV: Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis (clinicaltrials.gov) - Mar 27, 2018
P2, N=130, Recruiting, Sponsor: Blokhin's Russian Cancer Research Center
- ||| aprepitant oral / Generic mfg.
New P3 trial: A multicenter, open-label, uncontrolled study for the prevention of chemotherapy-induced nausea and vomiting (EUDRACT) - Mar 15, 2018
P3, N=22, , Sponsor: Ono Pharmaceutical Co., Ltd.
- | dexamethasone / Generic mfg., mirtazapine / Generic mfg.
Trial primary completion date: Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis (clinicaltrials.gov) - Jan 23, 2018
P3, N=212, Recruiting, Sponsor: Fudan University
Suspended --> Terminated; Study terminated due to no patient population available Trial primary completion date: Dec 2017 --> Dec 2018
- | ondansetron / Generic mfg.
Trial completion: AVERT: Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy (clinicaltrials.gov) - Dec 5, 2017
P2, N=52, Completed, Sponsor: University of Vermont
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- | aprepitant oral / Generic mfg.
New P1 trial: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers (clinicaltrials.gov) - Aug 9, 2017
P1, N=17, Not yet recruiting, Sponsor: The Hospital for Sick Children
- |||| ondansetron / Generic mfg., temozolomide / Generic mfg.
Trial completion, Trial initiation date, Combination therapy, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - May 30, 2017
P2, N=136, Completed, Sponsor: Katy Peters
Active, not recruiting --> Completed Recruiting --> Completed | Initiation date: Dec 2012 --> Jun 2014
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) (clinicaltrials.gov) - May 4, 2017
P3, N=820, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | Initiation date: Dec 2012 --> Jun 2014 No longer recruiting --> Completed
- |||| aprepitant oral / Generic mfg.
Trial completion: An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) (clinicaltrials.gov) - May 4, 2017
P4, N=866, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| NN1213 / Novo Nordisk
Trial completion: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) (clinicaltrials.gov) - May 4, 2017
P3, N=922, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| NN1213 / Novo Nordisk
Trial completion: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) (clinicaltrials.gov) - May 4, 2017
P3, N=805, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) (clinicaltrials.gov) - May 4, 2017
P3, N=600, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED) (clinicaltrials.gov) - May 4, 2017
P3, N=800, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073) (clinicaltrials.gov) - May 4, 2017
P3, N=324, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) (clinicaltrials.gov) - May 4, 2017
P3, N=540, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063) (clinicaltrials.gov) - May 4, 2017
P3, N=495, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED) (clinicaltrials.gov) - Apr 25, 2017
P3, N=900, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed